Ansun Biopharma is a Chinese biotechnology company. It announced completion of a 56 million yuan (about $80 million) Series B financing. The round was led by a cohort of venture capital firms including Oceanpine Capital, Junson Capital Company Limited and KIP. The article does not describe the company's specific products, pipeline, or therapeutic focus. It also does not disclose use of proceeds or operating metrics such as revenue or user counts. No founding year or past funding rounds are mentioned in the article. Ansun BioPharma is a clinical-stage biopharmaceutical company focused on developing DAS181, a potentially first‑in‑class broad‑spectrum antiviral biologic for respiratory viral infections including influenza, parainfluenza, and metapneumovirus. The company is advancing DAS181 through clinical development and is working with the U.S. FDA to plan and implement a Phase 3 trial of DAS181 for parainfluenza infection in hospitalized and immunocompromised patients. DAS181 has received Breakthrough Designation and Fast Track designation from the U.S. FDA for this indication. Ansun intends to use the proceeds from its recent financing to support the planned Phase 3 clinical trial. The company is led by interim CEO Dr. Nancy Chang. Ansun is based in San Diego, CA.

Total raised

$93M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2019